Acknowledgement of the positive repercussions of early diagnosis in treating diseases and preventing them through vaccination campaigns on people’s health and the sustainability of health systems has boosted this activity of Laboratorios LETI. Moreover, it has been extended to cover the diagnosis and prevention of Leishmaniasis (one of the most common parasitic diseases worldwide) and the growing field of assisted reproduction.

The development of technologies for producing flu vaccines using inactivated live viruses was an important technological step forward and earned LETI the recognition of the World Health Organisation as one of the main international flu vaccine manufacturers in the world. This culminated its consolidation in the vaccine sector. LETI plays an important role in supplying flu vaccines to governmental and regional health services and directly to hospitals, mutual insurance companies and pharmacies.

LETI launched the first quick urine tests for diagnosing infectious respiratory diseases in Spain, such as those arising from Legionella, Pneumococcus, VRS and A/B flu strains and for the diagnosis of Lyme disease.

Laboratorios LETI’s range of products for assisted reproduction holds an important place in this fast developing field with important prospects for the future.

LETI’s Diagnosis and Vaccines Division has just launched the first tests for diagnosing canine Leishmaniasis. In addition to diagnosing the parasitic infection, it can predict the course of the disease. Q Letitest comes in two formats consisting of a quick immunochromatographic test for screening the disease and the ELISA (Enzyme-Linked Immunosorbent Assay) test for monitoring and prognosis.